Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Spruce Biosciences Inc (SPRB)

Spruce Biosciences Inc (SPRB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
S&P Futures Climb Ahead of Key U.S. PPI and Retail Sales Data, Adobe Earnings on Tap

March S&P 500 E-Mini futures (ESH24) are trending up +0.37% this morning as market participants geared up for crucial U.S. PPI and retail sales data while also awaiting quarterly results from software...

ESH24 : 5,101.67s (-1.01%)
DLTR : 105.72 (-0.22%)
TSLA : 248.61 (+0.90%)
INTC : 31.97 (+2.37%)
SKIN : 2.0000 (+2.56%)
ADBE : 574.41 (+0.75%)
DG : 126.46 (+0.82%)
ULTA : 387.56 (-0.54%)
DKS : 198.66 (-0.73%)
ECV.D.DX : 17.060 (+0.29%)
SDF.D.DX : 12.460 (-0.95%)
S : 20.21 (+0.30%)
S&P Futures Tick Higher as Investors Weigh Interest Rate Outlook

September S&P 500 futures (ESU23) are trending up +0.08% this morning after the S&P 500 and Nasdaq closed in the red on Thursday as technology stocks dropped on concerns over the outlook for Apple, while...

ESU23 : 4,491.72s (-0.32%)
AAPL : 224.73 (+1.44%)
SWKS : 104.14 (-0.47%)
QCOM : 205.09 (+0.63%)
AI : 28.89 (+1.16%)
INTC : 31.97 (+2.37%)
MCD : 250.10 (+0.04%)
CCC.LN : 2,932.000 (-0.68%)
DOCU : 55.08 (+1.76%)
ADBE : 574.41 (+0.75%)
SMAR : 43.88 (+1.55%)
SWBI : 13.92 (-2.11%)
Spruce Biosciences to Present Findings on Retrospective Analysis of Completion Rates for CAH Studies at Pediatric Endocrine Society 2023 Annual Meeting

Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need,...

SPRB : 0.5600 (-0.88%)
Spruce Biosciences to Participate in May Investor Conferences

Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need,...

SPRB : 0.5600 (-0.88%)
Spruce Biosciences Reports Full Year 2022 Financial Results and Provides Corporate Updates

Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need,...

SPRB : 0.5600 (-0.88%)
Spruce Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need,...

SPRB : 0.5600 (-0.88%)
Spruce Biosciences Announces $53.6 Million Private Placement Financing

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need,...

SPRB : 0.5600 (-0.88%)
Spruce Biosciences to Participate in the SVB Securities Global Biopharma Conference

Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need,...

SPRB : 0.5600 (-0.88%)
Spruce Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023

Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need,...

SPRB : 0.5600 (-0.88%)
Spruce Biosciences (NASDAQ: SPRB) Enters Into Collaboration with Kaken Pharmaceutical to Develop Tildacerfont for CAH in Japan

Spruce Biosciences, Inc. (NASDAQ: SPRB) is engaged as a late-stage biopharmaceutical company, which is focused on the research, development and

SPRB : 0.5600 (-0.88%)

Barchart Exclusives

RSI Oversold: 2 Stocks (HOWL, WKHS) Potentially Signaling a Contrarian Buy
Sometimes equities that have been pushed too far down are at risk of surprisingly bouncing back. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar